Cited 0 times in
YAP1 Expression in HR+HER2- Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김지형 | - |
dc.contributor.author | 박인호 | - |
dc.contributor.author | 배숭준 | - |
dc.contributor.author | 안성귀 | - |
dc.contributor.author | 이양규 | - |
dc.contributor.author | 정준 | - |
dc.contributor.author | 차윤진 | - |
dc.date.accessioned | 2023-11-07T08:12:01Z | - |
dc.date.available | 2023-11-07T08:12:01Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196610 | - |
dc.description.abstract | Background: YAP1, an oncogene in numerous cancers, is a downstream transcription factor of the Hippo pathway. This study focuses on its relationship with the Oncotype Dx (ODX) test risk score (RS) in patients with hormone-receptor-positive, HER2-negative (HR+HER2-) breast cancer. Methods: We retrospectively analyzed 401 HR+HER2- breast cancer patients from Gangnam Severance Hospital who underwent ODX tests (May 2014-April 2020). YAP1 nuclear localization was evaluated via immunohistochemical staining and its clinical correlation with clinicopathological parameters, including RS, was analyzed. Public datasets TCGA-BRCA and METABRIC validated clinical outcomes. Results: YAP1 expression negatively correlated with ODX RS (OR 0.373, p = 0.002). Elevated YAP1 mRNA levels corresponded to better clinical outcomes, specifically in ER-positive patients, with significant results in METABRIC and TCGA-BRCA datasets (p < 0.0001 OS in METABRIC, p = 0.00085 RFS in METABRIC, p = 0.040 DFS in TCGA-BRCA). In subsets with varying ESR1 mRNA expression and pronounced YAP1 expression, superior survival outcomes were consistently observed. Conclusion: YAP1 may be a valuable prognostic marker and potential therapeutic target in HR+HER2- breast cancer patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CANCERS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | YAP1 Expression in HR+HER2- Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Inho Park | - |
dc.contributor.googleauthor | Yangkyu Lee | - |
dc.contributor.googleauthor | Jee Hung Kim | - |
dc.contributor.googleauthor | Soong June Bae | - |
dc.contributor.googleauthor | Sung Gwe Ahn | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.contributor.googleauthor | Yoon Jin Cha | - |
dc.identifier.doi | 10.3390/cancers15205034 | - |
dc.contributor.localId | A00999 | - |
dc.contributor.localId | A06092 | - |
dc.contributor.localId | A05345 | - |
dc.contributor.localId | A02231 | - |
dc.contributor.localId | A06080 | - |
dc.contributor.localId | A03727 | - |
dc.contributor.localId | A04001 | - |
dc.relation.journalcode | J03449 | - |
dc.identifier.eissn | 2072-6694 | - |
dc.identifier.pmid | 37894401 | - |
dc.subject.keyword | Yes-associated protein 1 | - |
dc.subject.keyword | breast neoplasms | - |
dc.subject.keyword | estrogen | - |
dc.subject.keyword | pathology | - |
dc.subject.keyword | prognosis | - |
dc.subject.keyword | receptors | - |
dc.contributor.alternativeName | Kim, Jee Hung | - |
dc.contributor.affiliatedAuthor | 김지형 | - |
dc.contributor.affiliatedAuthor | 박인호 | - |
dc.contributor.affiliatedAuthor | 배숭준 | - |
dc.contributor.affiliatedAuthor | 안성귀 | - |
dc.contributor.affiliatedAuthor | 이양규 | - |
dc.contributor.affiliatedAuthor | 정준 | - |
dc.contributor.affiliatedAuthor | 차윤진 | - |
dc.citation.volume | 15 | - |
dc.citation.number | 20 | - |
dc.citation.startPage | 5034 | - |
dc.identifier.bibliographicCitation | CANCERS, Vol.15(20) : 5034, 2023-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.